BenevolentAI, traded on Euronext Amsterdam under the ticker BAI, is a pioneering company at the forefront of integrating advanced artificial intelligence into the biopharmaceutical drug discovery process. With an innovative approach, BenevolentAI aims to transform how life science decision-makers and consultancies approach drug development. The company’s flagship platform, Qor, serves as a strategic resource that is always available to support biopharma professionals.

The brand is built on a strong philosophy that emphasizes the fusion of technology and science, harnessing the capabilities of AI and machine learning to enhance research outcomes. With over a decade of investment in proprietary knowledge systems, including a comprehensive knowledge graph and unique ontologies, BenevolentAI empowers scientists and industry leaders to navigate complex biopharmaceutical challenges confidently and precisely. Overall, BenevolentAI stands as a key player in the life sciences sector, committed to advancing drug discovery through intelligent technology solutions.